DiaMedica Therapeutics Inc. (DMAC) Stock Grade

About DiaMedica Therapeutics Inc.'s fundamentals

DiaMedica Therapeutics is a clinical-stage biotechnology company with a market capitalization of $374.0 million that is not yet profitable, having reported a net loss in its latest annual statement. The company currently generates no meaningful revenue, as evidenced by 0.0% year-over-year revenue growth and a 0.0% net margin. As a pre-revenue or early-stage biotech firm, DiaMedica does not pay dividends and traditional profitability metrics like P/E ratio and return on equity are not applicable at this stage of development.